Search
Genvida (Hangzhou) Biotechnology Co., Ltd. has recently announced the successful closure of its Series A funding round, raising tens of millions of yuan. Among the investors participating in this round are Hangzhou Huafang Capital, Wuhan Zhongneng Intelligent Healthcare, Changjin Holdings, and the Institute of Synthetic Biology at Nanjing Normal University. Established in 2022, Genvida specializes in the medical aesthetics and beauty industry, having developed a synthetic biology platform that adheres to pharmaceutical-grade quality standards. This latest funding injection will propel the commercialization of its recombinant collagen raw material products and foster partnerships with cosmetics industry enterprises, ultimately aiming to forge a cohesive 'science-product-industry' ecosystem.
-
C114 Communication Network -
Communication Home
